European Notebook: Pricing Reforms Debated In EU; Biosimilar Infliximab; AstraZeneca's HQ Build
Executive Summary
European policymakers look at options such as greater information exchange between countries to strengthen price negotiation, joint procurement, and more collaborative HTA reviews to help hold down the high prices of certain medicines; Hospira expands its biosimilar infliximab into major markets.
You may also be interested in...
Soriot’s Vision For AZ: A Focused Innovation-Driven Biopharma
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.